Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA ... Read More
Bausch + Lomb to acquire dry eye disease medication XIIDRA from Novartis
Bausch + Lomb has reached a definitive agreement with Novartis to acquire the non-steroid eye drop XIIDRA (lifitegrast ophthalmic solution) 5%, known for treating dry ... Read More
AbbVie acquisition of Allergan gets antitrust clearance from US FTC
AbbVie acquisition of Allergan update : US biopharma company AbbVie has secured clearance from the US Federal Trade Commission (FTC) for its previously announced $63 ... Read More
Allergan to acquire Bonti in strategic $195m deal to expand medical aesthetics pipeline
Irish pharmaceutical giant Allergan has announced its acquisition of Bonti, a U.S.-based aesthetic company specializing in fast-acting neurotoxin programs for aesthetic and therapeutic applications. The ... Read More